Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE)

Rimonabant treatment, examined in Phase 3 trials, showed improvement of cardiovascular risk factors in obese patients. The objective of this Phase 4 trial is to assess the effectiveness of rimonabant plus lifestyle counselling when used in daily practice, namely in the general practice. The hypothes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Family practice 2012-10, Vol.29 (5), p.521-527
Hauptverfasser:	Boesten, Jolien E J, Kaper, Janneke, Stoffers, Henri E J H, Kroon, Abraham A, van Schayck, Onno C P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anti-Obesity Agents - adverse effects Anti-Obesity Agents - therapeutic use Cardiovascular diseases Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Counseling Counselling Double-Blind Method Female General practice Humans Lifestyle Male Middle Aged Obesity Obesity - drug therapy Outcome Assessment (Health Care) Piperidines - adverse effects Piperidines - therapeutic use Primary Health Care Pyrazoles - adverse effects Pyrazoles - therapeutic use Quality of Life Risk Reduction Behavior Safety-Based Drug Withdrawals United Kingdom Waist Circumference - drug effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!